These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22454318)

  • 21. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.
    Radojkovic M; Tosic N; Colovic N; Ristic S; Pavlovic S; Colovic M
    Ann Clin Lab Sci; 2012; 42(2):186-90. PubMed ID: 22585616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [FLT3 mutations in children with acute myeloid leukemia: a single center study].
    Ruan M; Wang YQ; Zhang L; Liu TF; Liu F; Liu XM; Zhang JY; Zou Y; Chen YM; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):863-6. PubMed ID: 22099191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
    Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J; Wang T; Li S; Lin L; Gang Y
    Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
    Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
    Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
    Muñoz L; Aventín A; Villamor N; Juncà J; Acebedo G; Domingo A; Rozman M; Torres JP; Tormo M; Nomdedéu JF
    Haematologica; 2003 Jun; 88(6):637-45. PubMed ID: 12801839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
    Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
    J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation - Testing several different ITD sequences and rates, simultaneously.
    Mezei ZA; Tornai D; Földesi R; Madar L; Sümegi A; Papp M; Antal-Szalmás P
    J Biotechnol; 2019 Sep; 303():25-29. PubMed ID: 31302157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with
    Levis MJ; Perl AE; Altman JK; Gocke CD; Bahceci E; Hill J; Liu C; Xie Z; Carson AR; McClain V; Stenzel TT; Miller JE
    Blood Adv; 2018 Apr; 2(8):825-831. PubMed ID: 29643105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevalence and clinical significance of FLT3 internal tandem duplication mutation in acute leukemia].
    Wang LH; Zhou CL; Zhang XW; Chen S; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):393-6. PubMed ID: 15355689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
    Xu B; Shi PC; Song XY; Tang JH; Zhou SY
    Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information.
    Chou WC; Hou HA; Liu CY; Chen CY; Lin LI; Huang YN; Chao YC; Hsu CA; Huang CF; Tien HF
    Ann Oncol; 2011 Mar; 22(3):696-704. PubMed ID: 20693296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
    Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K
    Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
    Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
    J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.